
43.4 2020 Year in Review: The Law of Unintended Consequences Blesses NASH Drug Development
Roger Green discusses why despite widespread concerns, FDA’s Complete Response Letter to Intercept did not cripple progress in NASH drug development.
Roger Green discusses why despite widespread concerns, FDA’s Complete Response Letter to Intercept did not cripple progress in NASH drug development.
Stephen Harrison summarizes a year of progress in improving the tests and analyses used to derive clinical endpoints necessary to initial drug approvals
Mazen Noureddin describes a year in which biopsy’s shortcomings are revealed at the same time as non-invasive testing becomes better and produces more robust data
Vlad Ratziu discusses a “boiling hot” field of emerging NASH drugs and “particularly rich” data coming from no-invasive diagnostic testing
Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among